Trial results 23 January 2024 T-cell engagers enter new pivotal studies New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab. Read more
Conferences Trial results 9 December 2023 ASH 2023 – Bristol follows in Talvey’s slipstream Read more